Volume 18, Issue 42, July - December, 2024

Long-term neuroprotective efficacy of VEMSA-PD nasal drops: An innovative approach for management and mitigation of Parkinson’s disease symptoms

Muralidhar S Talkad^1♦, Aamir Javed¹, Vijay Satish¹, HV Anil Kumar², Kamal Saba³

¹R&D Centre, Vemsa Biotech Pvt. Ltd. #468, 39th cross, 9th main, 5th block Jayanagar, Bangalore 560041, Bengaluru, Karnataka, India
²Professor of Sericulture, Laboratory for Applied Biological Science, DVS College of arts and Science. Shimoga, Karnataka, India
³Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India

^♦Corresponding author
R&D Centre, Vemsa Biotech Pvt. Ltd. #468, 39th cross, 9th main, 5th block Jayanagar, Bangalore 560041, Bengaluru, Karnataka, India

ABSTRACT

Background and Purpose: Parkinson's Disease (PD) is a neurodegenerative disorder primarily affecting dopamine-producing neurons in the brain, leading to a spectrum of motor and non-motor symptoms. Methods: This study introduces VEMSA-PD nasal drops as a potential candidate, which, based on our investigations, has shown promising neuroprotective properties. VEMSA-PD nasal drops are a proprietary herbal compound enriched with micro-emulsions and bioactive components that are beneficial for the Central Nervous System (CNS) and managing PD. Our experimental model initially involved inducing PD in mice using 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine, administered at a dosage of 20 mg/kg (i.p) twice daily for five days. Result: Subsequent treatment with VEMSA-PD nasal drops revealed a significant neuroprotective effect. Notably, co-administration of MPTP with VEMSAPD (2 drops, 3 times/day) almost restored the striatum's glutathione (GSH) levels and antioxidant enzyme activity to normal levels in the MPTP-induced group (1.33 ± 0.06). Additionally, the elevated malondialdehyde (MDA) levels seen in the MPTPinduced group (8.11 ± 0.05) were considerably reduced in the group treated with VEMSA-PD, achieving MDA levels of 2.63 ± 0.143 in the striatum and 4.45 ± 0.169 in the treated group. Conclusion: Human PD patients received VEMSA-PD nasal drops for six months in the research. Uric acid levels decreased significantly pre-, fourmonth-, and post-treatment, suggesting VEMSA-PD may manage PD-related metabolic dysregulation. In conclusion, VEMSA-PD nasal drops reduce uric acid levels in human PD patients and protect neurons in animal models of PD.

Keywords: VEMSA-PD nasal drops, MPTP, Parkinson’s disease, oxidative stress, free radical, brain histopathology

Drug Discovery, 2024, 18(42), e17dd1993

PDF

DOI: https://doi.org/10.54905/disssi.v18i42.e17dd1993

Published: 16 August 2024